ASCO 2021: Summary Overview and Outlook 13|Special Research Express on Non-Small Cell Lung Cancer

ASCO 2021: Summary Overview and Outlook 12 | AstraZeneca’s latest data supports the ambition to radically change cancer outcomes through earlier treatment and changing patient experience

ASCO 2021: Summary Overview and Outlook 12 | AstraZeneca’s latest data supports the ambition to radically change cancer outcomes through earlier treatment and changing patient experience

Study 1: Multi-target cytotoxic T lymphocytes (MCTL) combined with teriprizumab as a second-line treatment of advanced non-small cell lung cancer ( NSCLC ) single-arm phase Ib study

Study 1: Multi-target cytotoxic T lymphocytes (MCTL) combined with teriprizumab as the second-line treatment of advanced non-small cell lung cancer ( NSCLC ) single-arm phase Ib study NSCLC

background

background

Anti-PD-1/PD-L1 mAb therapy has been approved as a second-line treatment for advanced NSCLC in the United States and Europe because of its better tolerability and efficacy compared with docetaxel.

immunity

method

The researchers carried out a single-center, open-label, phase 1b trial, that is, combined with MCTL cells and teriprizumab (anti-PD-1 mAb) as a second-line treatment for advanced NSCLC.

result

From June 2019 to October 2020, 14 patients aged 43-70 years (median age 59 years) were enrolled.

in conclusion

Multi-target cytotoxic T lymphocytes (MCTL) combined with teriprizumab is used as a second-line treatment for advanced NSCLC, because it is well tolerated and the efficacy is encouraging.

For details, see: asco.

asco.

Study 2: Radiotherapy (RT) for advanced non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) detonated immunotherapy.

background

Preclinical models have proved that the combination of RT and immune checkpoint inhibitors (ICI) can produce specific CD8+ T cell phenotypes associated with tumor reactive populations, resulting in obvious tumor responses.

Tumor immunity

method

Patients with advanced NSCLC and HNSCC who have started using FDA- approved single-agent ICI are eligible.

FDA

result

Between October 2017 and January 2021, 43 patients were enrolled and 38 patients were included in this analysis.

The median follow-up time for patients without progressive disease (PD) was 11.

Fifty-two grade 3-5 adverse events (AEs) were reported in 21 subjects.

medsci.

Interim analysis showed that 6-month PFS is acceptable.

For details, see: asco.

asco.

Study 3: A single-arm phase Ib study of autologous cytokine-induced killer (CIK) cellular immunotherapy combined with phoxim plus chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)

background

Immune checkpoint inhibitors plus chemotherapy are effective for patients with advanced non-small cell lung cancer (NSCLC) without targeted mutations.
Autologous cytokine-induced killer cells (CIK) can restore anti-tumor immunity, thereby improving the treatment effect of patients.
Combining CIK cells with anti-PD-1 mAb plus chemotherapy may enhance the therapeutic effect of patients with advanced NSCLC.

method

This is a single-center, open-label, phase 1b trial of CIK cells combined with sintilimab (anti-PD-1 mAb) plus chemotherapy for patients with stage IIIB-IV NSCLC.
Systemic treatment-naïve patients received platinum-containing dual-drug chemotherapy, sintilimab and CIK cells plus chemotherapy every 3 weeks.
It lasts for 4 cycles, and then sintilimab and CIK cells undergo maintenance treatment until the disease progresses or unacceptable toxicity occurs.

result

From May 2019 to January 2021, 34 patients (19 squamous cell carcinoma and 15 non-squamous carcinoma NCSLC) were enrolled, aged 46-73 years (median age 64 years).

Among the 32 evaluable patients, ORR was 81.
3% (73.
7% for squamous cell carcinoma and 92.
3% for non-squamous NSCLC), and DCR was 100%.
Of the 25 PRs assessed by RECIST, 5 (23.
1%) proved CMR by PET-CT.
Of the 3 patients with brain metastases, 2 had intracranial CR and 1 had PR.
At a median follow-up of 7.
5 months, the median DOR was not reached (range 0.
5m-NA), and the median PFS and OS were immature.
TRAE grade 3 or above includes pneumonia (n = 3); thrombocytopenia, leukopenia (n = 2 each); anemia, dysphagia, cardiomyopathy, and rash (n = 1).
The biomarkers and subgroups that are being analyzed related to efficacy and AEs include TMB, PDL1 expression, TILs distribution, cytokines, etc.

in conclusion

CIK cell therapy combined with Sintilimab and chemotherapy is well tolerated and shows encouraging effects.
Further research is needed to confirm these preliminary results.

For details, please refer to: asco.
org/record/196003/abstract">One-arm Phase Ib study of autologous cytokine-induced killer (CIK) cellular immunotherapy combined with phoxim plus chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)

asco.
org/record/196003/abstract">A single-arm phase Ib study of autologous cytokine-induced killing (CIK) cellular immunotherapy combined with phoxim plus chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)

 

Leave a message here